LivaNova

LIVN

Market cap $3.48B

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible.

LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assigned VNS Therapy™, a LivaNova neuromodulation treatment for patients 4 years of age and older with Drug-Resistant Epilepsy (DRE) and focal seizures, to New Technology Ambulatory Payment Classification (APC) 1580 for new patient implants (NPIs) under the 2026 Medicare Hospital Outpatient Prospective Payment System.

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan. “We are confident in our ability to deliver on the targets we outlined today. LivaNova's talented team is focused on a revitalized innovation strategy and operational excellence,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “The leadership positions we hold in our.

LivaNova PLC ( LIVN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Vladimir Makatsaria - CEO & Director Alex Shvartsburg - Chief Financial Officer Ahmet Tezel - Chief Innovation Officer Conference Call Participants Michael Polark - Wolfe Research, LLC Adam Maeder - Piper Sandler & Co., Research Division Matthew Taylor - Jefferies LLC, Research Division Anthony Petrone - Mizuho Americas LLC David Rescott - Robert W. Baird & Co. Incorporated, Research Division Michael Matson - Needham & Company, LLC, Research Division John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to LivaNova plc Third Quarter 2025 Earnings Conference Call.

LivaNova (LIVN) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.9 per share a year ago.

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an organic basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.49 and adjusted dilut.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Wolfe Research Healthcare Conference 2025 in New York City. The presentation will take place Mon., Nov. 17, at 2:40 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register t.

LivaNova remains a 'BUY' with a raised price target of $61/share, reflecting strong recent results and long-term growth potential. LIVN delivered double-digit revenue growth, improved margins, and raised guidance, driven by Cardiopulmonary and Neuromodulation segment performance. Despite a 20% short-term return, I see further upside due to robust fundamentals, market expansion, and clinical milestones supporting the investment thesis.

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5, 2025, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To liste.